EUVIMEDObjevte EUVIMED
Crossref

Tri-Modal Anticancer Therapy via Mo 2 C-MXene-Based Hybrid Nanostructures: A Synergistic Strategy Against Triple-Negative Breast Cancer

Ayça Tunçel, Derya Ozel, Gül Kaya, Buse Sert, Osman Yilmaz, Safiye Aktas, Hatice Efsun Kolatan, Özde Gökbayrak, Cumhur Gökhan Ünlü, Kasim Ocakoglu iD, Fatma Yurt iD

ACS Applied Materials & Interfaces · 2025

DOI: 10.1021/acsami.5c16111 ↗

At a glance

Journal article in ACS Applied Materials & Interfaces, 2025. Written by Ayça Tunçel and 10 co-authors. Institution: Faculty of Engineering, Department of Engineering Fundamental Sciences, Tarsus University, Tarsus 33400, Türkiye. Major MEDLINE topics: Triple Negative Breast Neoplasms, Paclitaxel, Nanostructures, Molybdenum. Cited 4 times so far (Crossref); 58 references. Funded by: T??rkiye Bilimsel ve Teknolojik Arastirma Kurumu.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Triple-negative breast cancer (TNBC) is an aggressive tumor subtype that is resistant to conventional therapies due to the lack of targetable receptors. In this study, a paclitaxel (PTX)-loaded Mo2C@C@Fuc/Mo2C-MXene@Fuc hybrid nanosystem was developed, and the efficacy of a combined therapeutic approach, photothermal therapy (PTT), photodynamic therapy (PDT), and chemotherapy (CT) was evaluated in vitro and in vivo against TNBC. The PTX/Mo2C@C@Fuc/Mo2C-MXene@Fuc hybrid nanosystem exhibited high drug loading efficiency and stimuli-responsive release. At 96 h, PTX release reached 58.6% at pH 4.5 and 44.2% at pH 6.0, while NIR irradiation further enhanced the release to 66.3% and 51.0%, respectively, confirming the pH- and light-responsive drug delivery capability of the system. Under NIR irradiation (808 nm), the hybrid structure generated significant levels of reactive oxygen species (ROS), leading to pronounced apoptotic induction and reducing cell viability to 52.8% in 4T1 cells. Similarly, in MDA-MB-231 cells, NIR-assisted combination treatment decreased viability to 55.9%. In contrast, L929 normal fibroblast cells retained a viability of 75.4% under the same treatment conditions, indicating cytotoxicity. Tube formation assay results demonstrated that the hybrid system significantly inhibited vascular structure formation in HUVEC cells after 24 h of incubation. In vivo studies further confirmed that the PTX-loaded hybrid system combined with NIR irradiation induced 82% necrosis and 12.5% apoptosis within tumor tissues, ultimately resulting in complete macroscopic tumor regression. Overall, this study highlights the potential of Mo2C-MXene-based hybrid nanostructures as a biocompatible and therapeutic platform for synergistic PDT/PTT/CT combination therapy in TNBC treatment.

Subjects

MeSH terms (MEDLINE)

Triple Negative Breast NeoplasmsPaclitaxelNanostructuresMolybdenumAntineoplastic AgentsHumansAnimalsFemaleMiceCell Line, TumorPhotochemotherapyMice, Inbred BALB CCell SurvivalApoptosisReactive Oxygen SpeciesDrug LiberationDrug CarriersNitritesTransition Elements

Author keywords

Mo2C@C@Fuc/Mo2C-MXene@Fuc hybrid nanosystemcombined therapyphotodynamic therapy (PDT)photothermal therapy (PTT)reactive oxygen species (ROS)triple-negative breast cancer (TNBC)

Substances

PaclitaxelMolybdenumAntineoplastic AgentsReactive Oxygen SpeciesDrug CarriersMXeneNitritesTransition Elements

Authors and institutions

  • Faculty of Engineering, Department of Engineering Fundamental Sciences, Tarsus University, Tarsus 33400, Türkiye.
  • Institute Nuclear Science, Department of Nuclear Applications, Ege University, Bornova, Izmir 35100, Türkiye.
  • Institute of Health Sciences, Department of Laboratory Animals, Dokuz Eylül University, İzmir 35210, Türkiye.
  • Institute of Oncology, Department of Basic Oncology, Dokuz Eylul University, Izmir 35000, Türkiye.
  • Faculty of Technology, Department of Biomedical Engineering, Pamukkale University, Denizli 20070, Türkiye.

ORCID profiles: Kasim Ocakoglu, Fatma Yurt

Funding

  • T??rkiye Bilimsel ve Teknolojik Arastirma Kurumu

Cite

APA

Tunçel, A., Ozel, D., Kaya, G., Sert, B., Yilmaz, O., Aktas, S., Kolatan, H. E., Gökbayrak, Ö., Ünlü, C. G., Ocakoglu, K., & Yurt, F. (2025). Tri-Modal Anticancer Therapy via Mo 2 C-MXene-Based Hybrid Nanostructures: A Synergistic Strategy Against Triple-Negative Breast Cancer. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.5c16111

Vancouver

Tunçel A, Ozel D, Kaya G, Sert B, Yilmaz O, Aktas S, et al. Tri-Modal Anticancer Therapy via Mo 2 C-MXene-Based Hybrid Nanostructures: A Synergistic Strategy Against Triple-Negative Breast Cancer. ACS Applied Materials & Interfaces. 2025. doi:10.1021/acsami.5c16111

BibTeX
@article{Tunel2025,
  author = {Tunçel, Ayça and Ozel, Derya and Kaya, Gül and Sert, Buse and Yilmaz, Osman and Aktas, Safiye and Kolatan, Hatice Efsun and Gökbayrak, Özde and Ünlü, Cumhur Gökhan and Ocakoglu, Kasim and Yurt, Fatma},
  title = {Tri-Modal Anticancer Therapy via Mo 2 C-MXene-Based Hybrid Nanostructures: A Synergistic Strategy Against Triple-Negative Breast Cancer},
  journal = {ACS Applied Materials & Interfaces},
  year = {2025},
  doi = {10.1021/acsami.5c16111}
}
Start for free →